{"id":409359,"date":"2021-01-06T08:03:25","date_gmt":"2021-01-06T13:03:25","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=409359"},"modified":"2021-01-06T08:03:25","modified_gmt":"2021-01-06T13:03:25","slug":"yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","title":{"rendered":"Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, Jan.  06, 2021  (GLOBE NEWSWIRE) &#8212; Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Paulash Mohsen, Chief Business Officer, will present at the H.C. Wainwright Virtual BioConnect Conference.<\/p>\n<p>The presentation will be available on-demand via the conference portal and through the Company&#8217;s website at yumanity.com\/events beginning January 11, 2021 starting at 6:00am EST.<\/p>\n<p>\n        <strong>About Yumanity Therapeutics<\/strong><br \/>\n        <br \/>Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company\u2019s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\u2019s disease. Yumanity\u2019s drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. Yumanity\u2019s pipeline consists of additional programs focused on dementia with Lewy bodies, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig\u2019s disease), frontotemporal lobar dementia (FTLD), and Alzheimer\u2019s disease.<\/p>\n<p>For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=87IywhvXC1IW4SrmfN27RLJQoqsID3hub7PhamAvBpobiyWhqfd3mr8rIzSWxMfNAFAIWnBBL8YbWqerx9HT9g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.yumanity.com<\/a>.<\/p>\n<p>\n        <strong>Contacts<\/strong><br \/>\n        <br \/>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Burns McClellan, Inc.<br \/>John Grimaldi<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3B8brwXAtg3QuPe6gTwwmlPnxSC6pXUkYQCGHuiuTnwcT7kLy4Bycf5kPhTw0dXri4JcLMFrnIJ9AdmLSNiDaVipRFzC4RvJQ1MMAGeH364=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">jgrimaldi@burnsmc.com<\/a><br \/>(212) 213-0006<\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Burns McClellan, Inc.<br \/>Ryo Imai \/ Robert Flamm, Ph.D.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xzj0mhnVHZGv2oQ-CM6rHUKvknT-CemMgNObZQEHZLOQJMO1-ktYpMsCEJlN2qdBHrRWAymCcXf_O0QUa7AUKg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">rimai@burnsmc.com<\/a> \/ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Tvb7WlGY3cls6ywcxWwsm7oTzZHGW_1iuH9BBeAq5M5_d63wNVY7W1p-PjjSzqwSAkIXt6BWzspbU_D9ZnpGwhRHs4JCq_3key4Z-C2SmMA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">rflamm@burnsmc.com<\/a><br \/>(212) 213-0006<\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTIwNiMzOTA2Mjk5IzIyMDAzMDI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/474bb8a1-8ce1-437e-828b-ef9e02d2ed02\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) &#8212; Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Paulash Mohsen, Chief Business Officer, will present at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on-demand via the conference portal and through the Company&#8217;s website at yumanity.com\/events beginning January 11, 2021 starting at 6:00am EST. About Yumanity Therapeutics Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company\u2019s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\u2019s disease. Yumanity\u2019s drug discovery platform &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-409359","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) &#8212; Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Paulash Mohsen, Chief Business Officer, will present at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on-demand via the conference portal and through the Company&#8217;s website at yumanity.com\/events beginning January 11, 2021 starting at 6:00am EST. About Yumanity Therapeutics Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company\u2019s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\u2019s disease. Yumanity\u2019s drug discovery platform &hellip; Continue reading &quot;Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-06T13:03:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTIwNiMzOTA2Mjk5IzIyMDAzMDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference\",\"datePublished\":\"2021-01-06T13:03:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\"},\"wordCount\":223,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTIwNiMzOTA2Mjk5IzIyMDAzMDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\",\"name\":\"Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTIwNiMzOTA2Mjk5IzIyMDAzMDI=\",\"datePublished\":\"2021-01-06T13:03:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTIwNiMzOTA2Mjk5IzIyMDAzMDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTIwNiMzOTA2Mjk5IzIyMDAzMDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","og_locale":"en_US","og_type":"article","og_title":"Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk","og_description":"BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) &#8212; Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Paulash Mohsen, Chief Business Officer, will present at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on-demand via the conference portal and through the Company&#8217;s website at yumanity.com\/events beginning January 11, 2021 starting at 6:00am EST. About Yumanity Therapeutics Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company\u2019s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\u2019s disease. Yumanity\u2019s drug discovery platform &hellip; Continue reading \"Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-06T13:03:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTIwNiMzOTA2Mjk5IzIyMDAzMDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference","datePublished":"2021-01-06T13:03:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/"},"wordCount":223,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTIwNiMzOTA2Mjk5IzIyMDAzMDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","name":"Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTIwNiMzOTA2Mjk5IzIyMDAzMDI=","datePublished":"2021-01-06T13:03:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTIwNiMzOTA2Mjk5IzIyMDAzMDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTIwNiMzOTA2Mjk5IzIyMDAzMDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/yumanity-therapeutics-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=409359"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409359\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=409359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=409359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=409359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}